The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model

Daniel H. Farkas, Nicholas E. Miltgen, Jay Stoerker, Dirk Van Den Boom, W. Edward Highsmith, Lesley Cagasan, Ron McCullough, Reinhold Mueller, Lin Tang, John Tynan, Courtney Tate, Allan Bombard

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

We designed a laboratory developed test (LDT) by using an open platform for mutation/polymorphism detection. Using a 108-member (mutation plus variant) cystic fibrosis carrier screening panel as a model, we completed the last phase of LDT validation by using matrix-assisted laser desorption/ionization time of flight mass spectrometry. Panel customization was accomplished via specific amplification primer and extension probe design. Amplified genomic DNA was subjected to allele specific, single base extension endpoint analysis by mass spectrometry for inspection of the cystic fibrosis transmembrane regulator gene (NM-000492.3). The panel of mutations and variants was tested against 386 blinded samples supplied by "authority" laboratories highly experienced in cystic fibrosis transmembrane regulator genotyping; >98% concordance was observed. All discrepant and discordant results were resolved satisfactorily. Taken together, these results describe the concluding portion of the LDT validation process and the use of mass spectrometry to detect a large number of complex reactions within a single run as well as its suitability as a platform appropriate for interrogation of scores to hundreds of targets.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalJournal of Molecular Diagnostics
Volume12
Issue number5
DOIs
StatePublished - Sep 2010

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Molecular Medicine

Fingerprint

Dive into the research topics of 'The suitability of matrix assisted laser desorption/ionization time of flight mass spectrometry in a laboratory developed test using cystic fibrosis carrier screening as a model'. Together they form a unique fingerprint.

Cite this